HRP20190540T1 - Postupak za pripremu spoja diariltiohidantoina - Google Patents
Postupak za pripremu spoja diariltiohidantoina Download PDFInfo
- Publication number
- HRP20190540T1 HRP20190540T1 HRP20190540TT HRP20190540T HRP20190540T1 HR P20190540 T1 HRP20190540 T1 HR P20190540T1 HR P20190540T T HRP20190540T T HR P20190540TT HR P20190540 T HRP20190540 T HR P20190540T HR P20190540 T1 HRP20190540 T1 HR P20190540T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- copper
- group
- organic solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
- B01J27/198—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094436P | 2014-12-19 | 2014-12-19 | |
| PCT/US2015/066356 WO2016100652A2 (en) | 2014-12-19 | 2015-12-17 | Process for the preparation of a diarylthiohydantoin compound |
| EP15823875.8A EP3233803B1 (en) | 2014-12-19 | 2015-12-17 | Process for the preparation of a diarylthiohydantoin compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190540T1 true HRP20190540T1 (hr) | 2019-06-14 |
Family
ID=55168400
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190540TT HRP20190540T1 (hr) | 2014-12-19 | 2015-12-17 | Postupak za pripremu spoja diariltiohidantoina |
| HRP20220750TT HRP20220750T1 (hr) | 2014-12-19 | 2015-12-17 | Postupak za proizvodnju spoja diariltiohidantoina |
| HRP20201847TT HRP20201847T2 (hr) | 2014-12-19 | 2020-11-20 | Postupak za pripremu spoja diariltiohidantoina |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220750TT HRP20220750T1 (hr) | 2014-12-19 | 2015-12-17 | Postupak za proizvodnju spoja diariltiohidantoina |
| HRP20201847TT HRP20201847T2 (hr) | 2014-12-19 | 2020-11-20 | Postupak za pripremu spoja diariltiohidantoina |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9688655B2 (https=) |
| EP (4) | EP3372585B1 (https=) |
| JP (2) | JP6681902B2 (https=) |
| KR (1) | KR102586059B1 (https=) |
| CN (2) | CN107108507B (https=) |
| AR (2) | AR103228A1 (https=) |
| AU (1) | AU2015364537B2 (https=) |
| BR (1) | BR112017013113B1 (https=) |
| CY (3) | CY1121684T1 (https=) |
| DK (3) | DK3372584T5 (https=) |
| EA (4) | EA201892485A1 (https=) |
| ES (3) | ES2718539T3 (https=) |
| HR (3) | HRP20190540T1 (https=) |
| HU (2) | HUE042409T2 (https=) |
| IL (1) | IL252843B2 (https=) |
| LT (3) | LT3372585T (https=) |
| MA (1) | MA41200B1 (https=) |
| MD (1) | MD3233803T2 (https=) |
| ME (1) | ME03420B (https=) |
| MX (1) | MX375467B (https=) |
| NZ (1) | NZ732766A (https=) |
| PH (1) | PH12017501152B1 (https=) |
| PL (3) | PL3233803T3 (https=) |
| PT (3) | PT3233803T (https=) |
| RS (3) | RS61060B9 (https=) |
| SG (4) | SG10201912811QA (https=) |
| SI (3) | SI3233803T1 (https=) |
| SM (3) | SMT202000618T1 (https=) |
| TR (1) | TR201904739T4 (https=) |
| TW (4) | TWI703132B (https=) |
| UA (1) | UA123201C2 (https=) |
| WO (1) | WO2016100652A2 (https=) |
| ZA (1) | ZA201704877B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383748B (es) | 2014-12-19 | 2025-03-14 | Aragon Pharmaceuticals Inc | Procesos para la preparación de un compuesto de diariltiohidantoína. |
| EP3372585B1 (en) * | 2014-12-19 | 2022-03-30 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| CN108383749B (zh) * | 2018-01-30 | 2021-03-09 | 杭州科巢生物科技有限公司 | 阿帕鲁胺的合成方法及其中间体 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法 |
| CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN110511206A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN110511207A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN113968815B (zh) * | 2020-07-24 | 2025-11-18 | 苏州科伦药物研究有限公司 | 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法 |
| EP4541786A3 (en) | 2020-09-04 | 2025-08-06 | Synthon B.V. | Improved process for preparation of apalutamide |
| CN116507624A (zh) | 2020-11-20 | 2023-07-28 | 美国安进公司 | 制备7-氯-6-氟-1-(2-异丙基-4-甲基吡啶-3-基)吡啶并f[2,3-d]嘧啶-2,4(1h,3h)-二酮的方法 |
| CN113402466B (zh) * | 2021-06-18 | 2022-08-16 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 |
| CN113292535B (zh) * | 2021-06-18 | 2022-07-01 | 南京方生和医药科技有限公司 | 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法 |
| CN115572264B (zh) * | 2021-07-06 | 2025-12-05 | 山东新时代药业有限公司 | 一种恩杂鲁胺的制备方法 |
| CN115850233B (zh) * | 2021-09-24 | 2024-12-10 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺的合成方法 |
| CN116239536A (zh) * | 2021-12-08 | 2023-06-09 | 山东新时代药业有限公司 | 一种阿帕鲁胺中间体化合物 |
| CN117534652A (zh) * | 2022-08-02 | 2024-02-09 | 黄冈人福药业有限责任公司 | 一种阿帕他胺的制备方法 |
| CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
| CN116332907A (zh) * | 2023-03-16 | 2023-06-27 | 奥锐特药业股份有限公司 | 一种无定形阿帕他胺的制备方法 |
| CN117645572A (zh) * | 2023-11-23 | 2024-03-05 | 奥锐特药业股份有限公司 | 恩扎卢胺及其中间体的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| BRPI0912802A2 (pt) * | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| EP2509961B1 (en) | 2009-12-11 | 2016-03-09 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| WO2011103202A2 (en) * | 2010-02-16 | 2011-08-25 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| PL2538785T3 (pl) * | 2010-02-24 | 2018-08-31 | Medivation Prostate Therapeutics Llc | Sposoby syntezy zwiazków diarylotiohydantoinowych i diarylohydantoinowych |
| DK2683694T3 (en) | 2011-03-10 | 2016-07-18 | Suzhou Kintor Pharmaceuticals Inc | ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| CA2908236C (en) * | 2012-03-29 | 2021-10-26 | Schindler, William | Diaspirin crosslinked pegylated hemoglobin |
| JP6469092B2 (ja) | 2013-05-29 | 2019-02-13 | ヒノバ ファーマシューティカルズ インコーポレイテッド | イミダゾリジンジオン化合物及び薬物組成物 |
| EP3372585B1 (en) * | 2014-12-19 | 2022-03-30 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
-
2015
- 2015-12-17 EP EP18169895.2A patent/EP3372585B1/en active Active
- 2015-12-17 SI SI201530599T patent/SI3233803T1/sl unknown
- 2015-12-17 MA MA41200A patent/MA41200B1/fr unknown
- 2015-12-17 EA EA201892485A patent/EA201892485A1/ru unknown
- 2015-12-17 PL PL15823875T patent/PL3233803T3/pl unknown
- 2015-12-17 WO PCT/US2015/066356 patent/WO2016100652A2/en not_active Ceased
- 2015-12-17 EP EP18170050.1A patent/EP3372586A1/en not_active Withdrawn
- 2015-12-17 PH PH1/2017/501152A patent/PH12017501152B1/en unknown
- 2015-12-17 SI SI201531848T patent/SI3372585T1/sl unknown
- 2015-12-17 LT LTEP18169895.2T patent/LT3372585T/lt unknown
- 2015-12-17 BR BR112017013113-7A patent/BR112017013113B1/pt active IP Right Grant
- 2015-12-17 MX MX2017008179A patent/MX375467B/es active IP Right Grant
- 2015-12-17 HU HUE15823875A patent/HUE042409T2/hu unknown
- 2015-12-17 PT PT15823875T patent/PT3233803T/pt unknown
- 2015-12-17 SG SG10201912811QA patent/SG10201912811QA/en unknown
- 2015-12-17 SM SM20200618T patent/SMT202000618T1/it unknown
- 2015-12-17 SG SG10201912805SA patent/SG10201912805SA/en unknown
- 2015-12-17 EA EA201892487A patent/EA201892487A1/ru unknown
- 2015-12-17 DK DK18169756.6T patent/DK3372584T5/da active
- 2015-12-17 DK DK15823875.8T patent/DK3233803T3/en active
- 2015-12-17 US US14/973,089 patent/US9688655B2/en active Active
- 2015-12-17 HR HRP20190540TT patent/HRP20190540T1/hr unknown
- 2015-12-17 SM SM20220242T patent/SMT202200242T1/it unknown
- 2015-12-17 UA UAA201707588A patent/UA123201C2/uk unknown
- 2015-12-17 ES ES15823875T patent/ES2718539T3/es active Active
- 2015-12-17 DK DK18169895.2T patent/DK3372585T3/da active
- 2015-12-17 KR KR1020177019551A patent/KR102586059B1/ko active Active
- 2015-12-17 ES ES18169756T patent/ES2827549T3/es active Active
- 2015-12-17 TR TR2019/04739T patent/TR201904739T4/tr unknown
- 2015-12-17 RS RS20201378A patent/RS61060B9/sr unknown
- 2015-12-17 EA EA201892486A patent/EA201892486A1/ru unknown
- 2015-12-17 PL PL18169895.2T patent/PL3372585T3/pl unknown
- 2015-12-17 RS RS20190350A patent/RS58454B1/sr unknown
- 2015-12-17 SG SG11201704969QA patent/SG11201704969QA/en unknown
- 2015-12-17 EP EP15823875.8A patent/EP3233803B1/en active Active
- 2015-12-17 AU AU2015364537A patent/AU2015364537B2/en active Active
- 2015-12-17 HR HRP20220750TT patent/HRP20220750T1/hr unknown
- 2015-12-17 EP EP18169756.6A patent/EP3372584B9/en active Active
- 2015-12-17 NZ NZ732766A patent/NZ732766A/en unknown
- 2015-12-17 JP JP2017532725A patent/JP6681902B2/ja active Active
- 2015-12-17 LT LTEP15823875.8T patent/LT3233803T/lt unknown
- 2015-12-17 SM SM20190208T patent/SMT201900208T1/it unknown
- 2015-12-17 SI SI201531433T patent/SI3372584T1/sl unknown
- 2015-12-17 SG SG10201912802XA patent/SG10201912802XA/en unknown
- 2015-12-17 CN CN201580069602.5A patent/CN107108507B/zh active Active
- 2015-12-17 PT PT181697566T patent/PT3372584T/pt unknown
- 2015-12-17 EA EA201791390A patent/EA201791390A1/ru unknown
- 2015-12-17 CN CN202410667649.2A patent/CN118638097A/zh active Pending
- 2015-12-17 PT PT181698952T patent/PT3372585T/pt unknown
- 2015-12-17 ME MEP-2019-86A patent/ME03420B/me unknown
- 2015-12-17 MD MDE20170208T patent/MD3233803T2/ro unknown
- 2015-12-17 HU HUE18169756A patent/HUE052475T2/hu unknown
- 2015-12-17 ES ES18169895T patent/ES2919951T3/es active Active
- 2015-12-17 PL PL18169756T patent/PL3372584T3/pl unknown
- 2015-12-17 LT LTEP18169756.6T patent/LT3372584T/lt unknown
- 2015-12-17 IL IL252843A patent/IL252843B2/en unknown
- 2015-12-17 RS RS20220542A patent/RS63455B1/sr unknown
- 2015-12-18 TW TW108131622A patent/TWI703132B/zh active
- 2015-12-18 TW TW108131623A patent/TWI689494B/zh active
- 2015-12-18 TW TW108146841A patent/TWI753336B/zh active
- 2015-12-18 TW TW104142692A patent/TWI683810B/zh active
- 2015-12-21 AR ARP150104237A patent/AR103228A1/es active IP Right Grant
-
2017
- 2017-07-18 ZA ZA2017/04877A patent/ZA201704877B/en unknown
-
2019
- 2019-04-10 CY CY20191100400T patent/CY1121684T1/el unknown
-
2020
- 2020-03-24 JP JP2020052658A patent/JP6903785B2/ja active Active
- 2020-11-02 CY CY20201101031T patent/CY1123611T1/el unknown
- 2020-11-20 HR HRP20201847TT patent/HRP20201847T2/hr unknown
-
2022
- 2022-06-10 CY CY20221100408T patent/CY1125243T1/el unknown
-
2024
- 2024-12-06 AR ARP240103372A patent/AR134579A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190540T1 (hr) | Postupak za pripremu spoja diariltiohidantoina | |
| JP2020114842A5 (https=) | ||
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20120830T1 (hr) | Imidazolkarboksamidi | |
| HRP20211041T1 (hr) | Anthelmintski depsipeptidni spojevi | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20180063T1 (hr) | Lipidirani derivati imidazokinolina | |
| AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| ME02323B (me) | Spiro supstituisana jedinjenja kao inhibitori angiogeneze | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| ES2381683T3 (es) | Compuestos de espiro-oxindol y sus usos como agentes terapéuticos | |
| AR063258A1 (es) | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. | |
| TW200716524A (en) | C5a receptor antagonists | |
| MX2011009806A (es) | Nuevos derivados de indazol inhibidores de hsp90, composiciones que los contienen y su uso. | |
| HRP20231092T1 (hr) | Inhibitori arginaze i postupci njihove primjene | |
| ME02682B (me) | Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa c | |
| TW200606154A (en) | Mercaptoimidazoles as CCR2 receptor antagonists | |
| PE20081554A1 (es) | S-nitrosotioles estables, procedimiento de sintesis y uso | |
| TW200606155A (en) | Mercaptoimidazoles as CCR2 receptor antagonists | |
| CA2970937C (en) | Process for the preparation of a diarylthiohydantoin compound | |
| JP2013010735A (ja) | １，２，４−トリアゾール化合物及びグアニジン誘導体の合成方法 | |
| Piven et al. | ffl SYNTHESIS OF NOVEL TRIFLUOROMETHYL-CONTAINING N, O-HETEROCYCLES | |
| NZ739711A (en) | Substituted amino triazoles useful as human chitinase inhibitors | |
| TH2001001596A (th) | สารประกอบเฮเทอโรไซคลิกในฐานะตัวยับยั้ง pad |